Moteur de recherche d’entreprises européennes
Financement de l’UE (9 974 294 €) : Consortium indo-européen pour l’innovation dans le vaccin antigrippal de nouvelle génération Hor10/02/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Consortium indo-européen pour l’innovation dans le vaccin antigrippal de nouvelle génération
The highly integrated INCENTIVE consortium represents true partnership between Indian and European/US groups that addresses the global health and economic challenge posed by influenza infections, to reduce the worldwide burden resulting from outbreaks. INCENTIVE’s strategic goals are to provide seminal knowledge on the underlying mechanisms of poor responsiveness to influenza vaccines in vulnerable individuals and advance the development of two next generation universal influenza vaccines. This is achieved by pursing the following specific objectives: 1) address the current knowledge gap by performing comprehensive immunome profiling of responders and non-responders to licensed influenza vaccines in infants, children, adults and elderly in parallel phase IV trials in Europe and India to identify the underlying mechanisms of vaccine responsiveness in different vulnerable populations and ethnical groups; 2) advance the development of two next generation universal vaccines, including an antigen presenting cell-targeted nucleic acid vaccine up to proof-of-concept for vaccine efficacy in non-human primates, and a computationally-derived second generation COBRA (Computationally-Optimized Broadly-Reactive Antigens) vaccine up to clinical development, comprising a phase I trial in Europe, a phase II trial in India and efficacy studies using an influenza controlled human challenge model; 3) identify predictive biomarkers of responsiveness to vaccination to develop new diagnostics; 4) implement comprehensive technology transfer and harmonization activities for immunological analysis and data integration; and 5) perform a health systems and investment analysis, and discrete choice experiments to assess the suitability of the developed technologies for low- and middle-income countries and to identify potential downstream constraints that might affect uptake by health care systems.
| ASA SPEZIALENZYME GmbH | 387 750 € |
| Academisch Ziekenhuis Leiden | 1 003 785 € |
| 531 859 € | |
| 136 875 € | |
| 383 670 € | |
| HELMHOLTZ-ZENTRUM für INFEKTIONSFORSCHUNG GmbH | 2 537 798 € |
| Helse Bergen HF | 0,00 € |
| 760 705 € | |
| 0,00 € | |
| Institut Pasteur | 441 260 € |
| 0,00 € | |
| 0,00 € | |
| 0,00 € | |
| 0,00 € | |
| 794 313 € | |
| 0,00 € | |
| 586 990 € | |
| Universite Libre de Bruxelles | 614 964 € |
| Universiteit Antwerpen | 919 944 € |
| Universitetet I Bergen | 567 296 € |
| Universitetet I Oslo | 307 086 € |
https://cordis.europa.eu/project/id/874866
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ASA SPEZIALENZYME GmbH - Financement de l’UE (9 974 294 €) : Consortium indo-européen pour l’innovation dans le vaccin antigrippal de nouvelle génération"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
